Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | CA9 | Q16790 | 5/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9065236 | 0.77 | LMNA (0.40) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL6131543 | 0.76 | LMNA (0.47) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL8557859 | 0.76 | LMNA (0.35) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL6131548 | 0.75 | CA12 (0.44) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL6131613 | 0.74 | LMNA (0.47) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL6131592 | 0.74 | CYP2C19 (0.53) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL6131623 | 0.73 | KMT2A (0.54) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL3843843 | 0.72 | KMT2A (0.45) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL6131546 | 0.72 | KMT2A (0.45) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL5310582 | 0.72 | KMT2A (0.45) | LMNATHRBCYP2C19KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | claimed |
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2002-05-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | LMNA 4114/4885THRB 618/4885CYP2C19 4764/4885 |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | HIF1A, HIF1AN, SLC2A8 | LMNA 4114/4885THRB 618/4885CYP2C19 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.